Shanghai, China, 14 April 2025 – Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort EP") announces that its EasyEcho™ Ultrasound Catheter has been approved for fast-track registration as an innovative medical device by China’s National Medical Product Administration (NMPA) . This approval places the catheter on the NMPA Green Channel, expediting its regulatory review process.

ICE technology represents the cutting edge of cardiac electrophysiology. By placing a miniature ultrasound transducer at the tip of the catheter and delivering it via peripheral vessels (such as veins) into the heart chamber, ICE enables real-time, radiation-free, high-resolution imaging of intracardiac structures and major vessels. This technology significantly reduces radiation exposure, minimizes complications, and shortens both recovery and hospitalization time for patients undergoing cardiac procedures.

The EasyEcho™ featured 3D ultrasound localization and works in synergy with ultrasound imaging systems and MicroPort EP’s Columbus™ 3D EP Navigation System. This integration enables precise intraoperative visualization, capturing detailed structural and device images alongside accurate 3D positioning, which enhances procedural safety and clinical outcomes.

Currently undergoing pre-market clinical trials in China, EasyEcho™ is set to benefit patients with tachyarrhythmia once approved. Its inclusion in the NMPA Innovation Pathway accelerates the regulatory process, expanding procedural options for physicians and improving patient outcomes.

MicroPort EP remains committed to driving forward technological innovation in electrophysiology, delivering world-class, integrated interventional solutions that empower both physicians and patients with reliable medical care.